Protocol Ledger

NCT03962543 · Phase II · ACTIVE NOT RECRUITING

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Interventional Phase II clinical trial protocol NCT03962543 sponsored by EMD Serono / Merck KGaA in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-29 Enrollment: 114 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03962543
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)114 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03962543
Protocol FieldVerified Registry Value
NCT IdentifierNCT03962543
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment114 participants (ACTUAL)
Registered Start Date2019-09-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI